Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
PYPD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
7 hours ago
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
seekingalpha.com
16 hours ago
globenewswire.com
19 hours ago
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-3.90
vs -18.32
Q3.23
N/A
-3.40
vs -14.41
Q4.23
N/A
-3.97
vs -9.61
Q1.24
N/A
-1.37
vs -8.41
Q2.24
N/A
-1.25
vs -3.90
Q3.24
N/A
-1.22
vs -3.40
Q4.24
N/A
NA
vs -3.97
Q1.25
N/A
-0.70
vs -1.37
Q2.25
N/A
-0.55
vs -1.25
Q3.25
N/A
-0.52
vs -1.22
Sales Growth
YoY
Current
Estimates
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
NA vs NA
Q1.25
NA
NA vs NA
Return on Equity
QoQ
Q4.22
-111%
-1.11
vs -0.81
Q1.23
-53%
-0.53
vs -1.11
Q2.23
-70%
-0.70
vs -0.53
Q3.23
-158%
-1.58
vs -0.70
Q4.23
+303%
3.03
vs -1.58
Q1.24
-90%
-0.90
vs 3.03
Q2.24
-393%
-3.93
vs -0.90
Q3.24
-360%
-3.60
vs -3.93
Q4.24
-111%
-1.11
vs -3.60
Q1.25
-9614%
-96.14
vs -1.11
Institutionnal Ownership
QoQ
Q1.21
20
20
vs 19
5%
Q2.21
22
22
vs 20
10%
Q3.21
19
19
vs 22
-14%
Q4.21
30
30
vs 19
58%
Q1.22
31
31
vs 30
3%
Q2.22
30
30
vs 31
-3%
Q3.22
21
21
vs 30
-30%
Q4.22
14
14
vs 21
-33%
Q1.23
10
10
vs 14
-29%
Q2.23
13
13
vs 10
30%
Quote Panel
Key Metrics
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
NASDAQ
Unprofitable
Unprofitable
0.06 ( 1.74%)
After-hours 3.55$0.04 (1.28%)
Relative Strenght
79
Volume Buzz
-88%
Earning Acce
Yes
Dist 52w H.
11%Relative Strength
PYPD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
2026-Revenue
-127%2026-EPS
2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
9.00(156.41%)
Number of analyst
1
Last analyst upgrade/downgrade
Craig-Hallum
initialisePrevious: Not converted
2024-11-04
Now: Buy
Raymond James
downgradePrevious: Not converted
2022-09-06
Now: Outperform
Guggenheim
upgradePrevious: Not converted
2022-09-02
Now: Neutral